search
for
 About Bioline  All Journals  Testimonials  Membership  News


Journal of Cancer Research and Therapeutics
Medknow Publications on behalf of the Association of Radiation Oncologists of India (AROI)
ISSN: 0973-1482 EISSN: 1998-4138
Vol. 4, Num. 1, 2008, pp. 37-38

Journal of Cancer Research and Therapeutics, Vol. 4, No. 1, January-March, 2008, pp. 37-38

Case Report

Radiotherapy for management of skin cancers in fibrodysplasia ossificans progressiva: A case report and review of the literature

John Antony Frew, Charles G Kelly

NCCT, Newcastle General Hospital, Newcastle upon Tyne, NE4 6BE
Correspondence Address: NCCT, Newcastle General Hospital, Newcastle upon Tyne, NE4 6BE
john.frew@nuth.nhs.uk

Code Number: cr08008

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a rare condition of ectopic calcification leading to increasing disability throughout life, with most patients being wheelchair bound by the age of 30. Ectopic calcification can be triggered by trauma and it is therefore important to minimize biopsies and operative procedures in affected individuals. We report a 46-year-old FOP patient who was successfully treated with radiotherapy for a basal cell carcinoma. There are no previous reports in the literature on the management of skin malignancies in these patients and very limited literature on outcome following external beam radiotherapy.

Keywords: Basal cell carcinoma, fibrodysplasia ossificans progressiva, radiotherapy

Introduction

Fibrodysplasia ossificans progressiva (FOP), also known as myositis ossificans progressiva, is a rare condition of ectopic ossification, with only around 300 known patients worldwide. There are no reports on the management of skin malignancies in these patients and very limited literature on outcome following external beam radiotherapy.

Case History

A 46-year-old gentleman with a background of severe FOP, presented in April 2006 with a basal cell carcinoma (BCC) involving the right upper lip. The diagnosis was made on clinical grounds, with no biopsy being performed because of the risk of heterotopic bone formation following trauma. He was treated with superficial x-ray radiotherapy (90 kV) to a dose of 35 Gray delivered in five fractions on consecutive days. The patient had a complete response to radiotherapy, with a good cosmetic result; there was no evidence of heterotopic bone formation [Figure - 1].

Discussion

FOP has autosomal dominant inheritance with complete penetrance but variable expressivity, and most cases result from sporadic mutation. [1] Symptoms tend to begin in early childhood with tender swellings on the head, neck, or back. [2],[3] The diagnosis is supported in almost all patients by congenital malformations of the great toes. The malformations are recognizable at birth, and consist of a hypoplastic proximal phalanx with associated halux valgus. [4] Although ossification may not be evident early in the course of the disease, the swellings most often progress to ossification. The most common sites of early heterotopic ossification are the neck, spine, and shoulder girdle. Ossification tends to proceed in a cranial to caudal and proximal to distal pattern. The majority of patients have severely restricted movement of the upper limbs by the age of 15, with many confined to a wheelchair by 30 years of age.

The genetic mutation responsible for FOP has recently been mapped to chromosome 2q23-24 by linkage analysis in five families with unambiguous features of FOP. [5] This revealed an identical heterozygous mutation (617→ A; R206H) in the glycine-serine (GS) activation domain of ACVR1, a bone morphogenetic protein (BMP) type 1 receptor, in all the affected individuals examined. Protein modeling predicts destabilization of the GS domain, which is consistent with constitutive activation of the ACVR1 as the underlying cause of the ectopic chondrogenesis, osteogenesis, and joint fusions seen in FOP.

There is no effective treatment and it is, therefore, important to avoid soft tissue trauma, including biopsies, intramuscular injections, surgical procedures, and mandibular blocks for dental procedures; viral illnesses must also be avoided. [6] All of these are recognized factors that may precipitate episodes of rapidly progressive heterotopic ossification, with resultant permanent loss of function in the affected area. Early diagnosis and avoidance of trauma are the key principles in the effective management of these patients. There are no reports of the use of liquid nitrogen cryotherapy for the treatment of skin cancer in FOP patients. However, in view of the potential for this modality to cause significant tissue inflammation there is always the fear that this could result in further heterotopic ossification.

A search of the PubMed database (of the National Library of Medicine) and Ovid MEDLINE did not locate any previous reports on the management of BCC in FOP patients. It is intuitive that the most appropriate management should be nonsurgical. Previous reports in the literature reveal similar outcomes following surgery or radiotherapy in the treatment of BCC.

Kitterman et al . [7] sent a questionnaire to all 269 patient-members of the International FOP Association which is believed to include over 90% of all known FOP patients worldwide. Of the 138 responders, 87% of patients were initially given incorrect diagnoses, the commonest of which was cancer (32%). Of these patients, seven received radiotherapy but the authors do not comment on the outcome.

There are two other case reports in the literature of treatment with radiotherapy in patients with FOP. Radiotherapy was given to prevent ossification following the excision of heterotopic bone from the ankylosed hip joint of an 18-year-old FOP patient. [6] There was a small amount of ossification at the operative site at 1 year, with a report of a good functional outcome. Radiotherapy was also effective in reducing the neuropraxia associated with an iliopsoas mass compressing the femoral nerve in an FOP patient. [8]

It is the opinion of the authors that fractionated radiotherapy should be considered the standard of care for FOP patients with BCC and that biopsy should be reserved for those patients in whom the clinical diagnosis is uncertain.

References

1.Kaplan FS, McCluskey W, Hahn G, Tabas JA, Muenke M, Zasloff MA. Genetic transmission of fibrodysplasia ossificans progressiva. J Bone Joint Surg Am 1993;75:1214-20.  Back to cited text no. 1  [PUBMED]  
2.Connor JM, Evans DA. Fibrodysplasia ossificans progressiva: The clinical features and natural history of 34 patients. J Bone Joint Surg Br 1982;64:76-83.  Back to cited text no. 2  [PUBMED]  [FULLTEXT]
3.Cohen RB, Hahn GV, Tabas JA, Peeper J, Levitz CL, Sando A, et al . The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. J Bone Joint Surg Am 1993;75:215-9.  Back to cited text no. 3  [PUBMED]  
4.Schroeder HW Jr, Zasloff M. The hand and foot malformations in fibrodysplasia ossificans progressiva. Johns Hopkins Med J 1980;147:73-8.  Back to cited text no. 4  [PUBMED]  
5.Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, et al . A recurrent mutation in the BMP type 1 receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressive. Nat Genet 2006;38:525-7.  Back to cited text no. 5  [PUBMED]  [FULLTEXT]
6.Benetos IS, Mavrogenis AF, Themistocleous GS, Kanellopoulos AD, Papagelopoulos PJ, Soucacos PN. Optimal treatment of fibrodysplasia ossificans progressiva with surgical excision of heterotopic bone, indomethacin and irradiation. J Surg Orthop Adv 2006;15:99-104.  Back to cited text no. 6  [PUBMED]  [FULLTEXT]
7.Kitterman JA, Kantanie S, Rocke DM, Kaplan FS. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics 2005;116:e654-61.  Back to cited text no. 7  [PUBMED]  [FULLTEXT]
8.Druce M, Morris VH, Stamp TC. A case of myositis ossificans progressiva complicated by femoral nerve compression treated with radiotherapy. Rheumatology (Oxford) 2002;41:947-8.  Back to cited text no. 8  [PUBMED]  [FULLTEXT]

Copyright 2008 - Journal of Cancer Research and Therapeutics


The following images related to this document are available:

Photo images

[cr08008f1.jpg]
Home Faq Resources Email Bioline
© Bioline International, 1989 - 2024, Site last up-dated on 01-Sep-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Google Cloud Platform, GCP, Brazil